(Reuters) - Neuralstem Inc said its stem-cell therapy significantly improved movement in rats with broken spines, increasing the likelihood of the technology being used to treat people with spinal cord injuries.
The company's shares rose 95 percent to a year-high of $1.95 in afternoon trading on the American Stock Exchange. They later pared some gains to trade at $1.40.
Results from an independent study, which used Neuralstem's cells, were published on the website of scientific journal CELL.
The company said the tested rodents regained movement in all their lower extremity joints as the stem cells helped connect the broken points of the spinal cord.
"The fact that these cells induce regeneration of axons (nerve fibers) and partial recovery of motor function makes them relevant for testing for the treatment of human spinal cord injury," the company's chief scientific officer, Karl Johe, said in a statement.
The company said it has applied with U.S. health regulators for approval to test these cells in its own spinal cord injury study.
The company recently completed an 18-patient study to test the same cells, codenamed NSI-566, to treat Lou Gehrig's disease, or ALS, a condition where nerve cells of the brain and spinal cord die, hampering the body's ability to control muscle movement.
Other companies that are developing treatments for ALS include Biogen Idec Inc, Cytokinetics Inc and BrainStorm Cell Therapeutics.
(Reporting by Adithya Venkatesan and Zeba Siddiqui in Bangalore; Editing by Don Sebastian)
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.